3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Breast
1
Conditions
Prostatic Neoplasms
3
Lung Neoplasms
3
Rectal Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumor, Adult
1
Sarcoma
1
Rhabdomyosarcoma
1
Pulmonary Fibrosis
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
pembrolizumab
26
Gemcitabine
20
Cisplatin
12
Nivolumab
11
Carboplatin
8
Paclitaxel
7
Docetaxel
7
atezolizumab
6
durvalumab
5
Radiotherapy
5
fludarabine
4
enfortumab vedotin
4
Ipilimumab
4
Cyclophosphamide
4
Vorinostat
3
Magnetic Resonance Spectroscopy
3
Fluorouracil
3
Filgrastim
3
Doxorubicin
3
zimberelimab
2
vocimagene amiretrorepvec
2
tremelimumab
2
romidepsin
2
poly ICLC
2
infigratinib
2
erdafitinib
2
cc-486
2
belinostat
2
avelumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Urinary Bladder Neoplasms
×
Positron-Emission Tomography
×
Clear all
NCT02437539
2015-08-24
uPAR-PET
Rigshospitalet, Denmark
Phase 1
Completed
10 enrolled